Skip to main content


The prospect of genetically modifying humans has loomed over the public for decades. Now, science fiction is becoming reality. New technology and expanding research are positioned to make genetic alteration a routine, pre-conception appointment. For several years, China has been experimenting with germline editing on non-viable human embryos. In April 2016, the UK also approved a group of scientists to begin similar research. In the United States, genetic engineering is a multibillion-dollar industry. Although ethical debates over human genetic modification have checked the industry, the potential for clinical trials has become a reality as companies race to dominate the technology. In light of the potential impact of problematic genetic alterations on future generations, the harm inflicted on victims parallels the Diethylstilbestrol cases of the 1980s, signaling a re-emergence of market share liability.


File nameDate UploadedVisibilityFile size
6 Sep 2022
712 kB



  • Subject
    • Food and Drug Law

    • Health Law and Policy

    • Medical Jurisprudence

    • Science and Technology Law

  • Journal title
    • Boston College Law Review

  • Volume
    • 59

  • Issue
    • 1

  • Pagination
    • 319

  • Date submitted

    6 September 2022